Anatomic resection and nodal assessment Review definitive surgery for operable early NSCLC. | Local treatment Care pathway | nci_nsclc, calgb140503 |
Definitive stereotactic radiation review Review SBRT for medically inoperable, node-negative early disease. | Local treatment Care pathway | nci_nsclc, rtog0236 |
Perioperative pembrolizumab plus platinum chemotherapy Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting. | Systemic therapy FDA-approved | peri_pembro, kn671_5y |
Perioperative nivolumab plus platinum chemotherapy Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting. | Systemic therapy FDA-approved | peri_nivo, cm77t, cm77t_ctgov |
Perioperative durvalumab plus platinum chemotherapy Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting. | Systemic therapy FDA-approved | peri_durva, aegean |
Adjuvant platinum-based chemotherapy Review adjuvant platinum after complete resection in the appropriate stage and treatment sequence. | Systemic therapy Care pathway | nci_nsclc, lace |
Adjuvant osimertinib EGFR exon 19 deletion or L858R after complete resection; chemotherapy decision remains separate. | Systemic therapy FDA-approved | tagrisso, adaura, tagrisso_coverage_20261109 |
Adjuvant alectinib ALK-positive disease after complete resection meeting the tumor-size or nodal criterion. | Systemic therapy FDA-approved | adj_alectinib, alecensa, alina, alecensa_coverage_20261109, alina_ctgov, elevate_2026 |
Adjuvant pembrolizumab after platinum Postoperative immunotherapy after complete resection and platinum, without prior neoadjuvant systemic therapy. | Systemic therapy FDA-approved | adj_pembro |
Adjuvant atezolizumab after platinum PD-L1-positive resected stage II–IIIA disease after platinum chemotherapy. | Systemic therapy FDA-approved | adj_atezo |
Concurrent platinum chemoradiation Multidisciplinary definitive treatment for unresectable stage III NSCLC. | Systemic therapy Care pathway | nci_nsclc |
Sequential platinum chemoradiation Multidisciplinary definitive treatment for unresectable stage III NSCLC. | Systemic therapy Care pathway | nci_nsclc |
Durvalumab after concurrent chemoradiation Consolidation after concurrent platinum chemoradiation without progression. | Systemic therapy FDA-approved | imfinzi, pacific5 |
Osimertinib after chemoradiation EGFR exon 19 deletion or L858R disease without progression after definitive platinum chemoradiation. | Systemic therapy FDA-approved | laura, laura_updated_2026 |
Osimertinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | tagrisso, flaura2_os, tagrisso_coverage_20261109 |
Osimertinib plus platinum/pemetrexed Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | osi_chemo, pemetrexed_label, flaura2_os |
Amivantamab plus lazertinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | ami_laz, mariposa_os, rybrevant_faspro_spl |
Amivantamab plus carboplatin/pemetrexed after EGFR TKI Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | ami_post, pemetrexed_label, rybrevant_faspro_spl |
Datopotamab deruxtecan after EGFR therapy and platinum Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | dato |
Amivantamab plus carboplatin/pemetrexed Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | ami_ex20, pemetrexed_label, rybrevant_faspro_spl |
Amivantamab after platinum Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | ami_ex20, chrysalis, rybrevant_faspro_spl |
Sunvozertinib after platinum Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | sunvo |
Alectinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | alecensa, alex, alecensa_coverage_20261109, alex_final_os_2025 |
Lorlatinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | lorbrena, crown5 |
Ensartinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | ensartinib, exalt3 |
Repotrectinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | repo, trident1 |
Taletrectinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | talet |
Zidesamtinib after a ROS1 inhibitor Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | zides |
Selpercatinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | retevmo, libretto431, libretto431_pmc |
Tepotinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | tepo, vision |
Encorafenib plus binimetinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | enco, pharos, pharos_os_2025 |
Zongertinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | zong |
Sevabertinib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | seva |
Trastuzumab deruxtecan after prior systemic treatment Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | tdxd, dl02, enhertu_label_o12 |
Sotorasib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | lumakras, cb200, cb200_ctgov, krascendo1_2026 |
Adagrasib Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | krazati, krystal12, krystal12_ctgov, krascendo1_2026 |
Larotrectinib for an NTRK fusion Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA-approved | laro, laro_lung |
Zenocutuzumab after prior treatment Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context. | Systemic therapy FDA accelerated approval | zeno |
Telisotuzumab vedotin for high c-MET expression Previously treated nonsquamous NSCLC meeting the exact approved c-MET protein-expression threshold. | Systemic therapy FDA accelerated approval | teliso |
Pembrolizumab plus pemetrexed/platinum First-line chemoimmunotherapy after molecular review in nonsquamous NSCLC. | Systemic therapy FDA-approved | kn189, nci_nsclc, pemetrexed_label, kn189_5y, persee_primary_20261025, persee_registry_20261109 |
Pembrolizumab plus carboplatin/taxane First-line chemoimmunotherapy after molecular review in squamous NSCLC. | Systemic therapy FDA-approved | kn407, nci_nsclc, kn407_5y, persee_primary_20261025, persee_registry_20261109 |
Pembrolizumab monotherapy for high PD-L1 Review a chemotherapy-free first-line option in driver-negative, high-PD-L1 disease. | Systemic therapy FDA-approved | nci_nsclc, kn024_5y, persee_primary_20261025, persee_registry_20261109 |
Platinum-doublet review when immunotherapy is unsuitable Review histology-appropriate cytotoxic treatment when a documented immunotherapy concern prevents an IO pathway. | Systemic therapy Care pathway | nci_nsclc |
SCLC resection followed by systemic-treatment review Rare early node-negative SCLC requires invasive staging and multidisciplinary surgical review. | Local treatment Care pathway | nci_sclc |
SCLC stereotactic radiation plus chemotherapy review Early node-negative medically inoperable SCLC may be reviewed for SBRT and systemic chemotherapy. | Local treatment Care pathway | nci_sclc |
Concurrent platinum/etoposide chemoradiation Combined systemic and thoracic treatment for eligible limited-stage SCLC. | Systemic therapy Care pathway | nci_sclc |
Durvalumab after limited-stage chemoradiation Limited-stage SCLC without progression after concurrent platinum chemoradiation. | Systemic therapy FDA-approved | adriatic, adriatic_primary |
Atezolizumab plus carboplatin/etoposide First-line extensive-stage SCLC induction followed by maintenance review. | Systemic therapy FDA-approved | im133, nci_sclc |
Durvalumab plus platinum/etoposide First-line extensive-stage SCLC with cisplatin or carboplatin plus etoposide. | Systemic therapy FDA-approved | imfinzi, caspian3 |
Atezolizumab maintenance Continue maintenance after the matching atezolizumab/carboplatin/etoposide induction. | Systemic therapy FDA-approved | im133, imforte, imforte_primary |
Lurbinectedin plus atezolizumab maintenance Maintenance intensification after matching induction without progression. | Systemic therapy FDA-approved | imforte, imforte_primary |
Durvalumab maintenance Continue maintenance only after the matching durvalumab-containing induction. | Systemic therapy FDA-approved | imfinzi |
Tarlatamab after platinum progression Review DLL3-directed treatment after platinum-based chemotherapy progression. | Systemic therapy FDA-approved | tarlatamab, imdelltra_label_v8 |
Relapsed SCLC chemotherapy review Grouped review of other salvage chemotherapy in context of interval, prior drugs and fitness. Topotecan and platinum rechallenge are shown as their own options; lurbinectedin alone is shown separately as off-label because its relapsed small-cell indication left the label in 09/2026. | Systemic therapy Care pathway | nci_sclc, tarlatamab |
Neoadjuvant-only nivolumab plus platinum chemotherapy CheckMate816: neoadjuvant treatment then planned surgery, without automatically adding postoperative nivolumab. | Source-supported additional alternative FDA-approved neoadjuvant pathway | cm816_os, opdivo_neo, cm816_registry |
Osimertinib plus savolitinib after osimertinib (SAFFRON) MET-selected post-osimertinib discussion requiring exact post-progression tissue criteria and access review. | Source-supported additional alternative Investigational US pathway; no FDA approval asserted | saffron, saffron_registry |
Tarlatamab plus durvalumab maintenance (DeLLphi-305) First-line maintenance only after matching durvalumab induction without progression; not the post-platinum relapse indication. | Source-supported additional alternative Off-label US maintenance pathway | d305, d305_registry, tarlatamab |
Brigatinib Source-qualified alternative for the specified molecular and treatment setting. | Systemic therapy FDA-approved | brigatinib_label_i7 |
Capmatinib Source-qualified alternative for the specified molecular and treatment setting. | Systemic therapy FDA-approved | capmatinib_label_i7 |
Dabrafenib plus trametinib Source-qualified alternative for the specified molecular and treatment setting. | Systemic therapy FDA-approved | dabrafenib_trametinib_label_i7 |
Lorlatinib after ALK-inhibitor treatment Source-qualified alternative for the specified molecular and treatment setting. | Systemic therapy FDA-approved | lorlatinib_post_alk_label_i7 |
Osimertinib for EGFR T790M after an earlier EGFR inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tagrisso_label_o12 |
Repotrectinib after a ROS1 inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | augtyro_label_o12 |
Taletrectinib after a ROS1 inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | ibtrozi_label_o12 |
Entrectinib Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | rozlytrek_label_o12 |
Crizotinib (ROS1-positive) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | xalkori_label_o12 |
Zongertinib after earlier treatment Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA accelerated approval | hernexeos_label_o12 |
Sevabertinib after earlier treatment Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA accelerated approval | hyrnuo_label_o12 |
Docetaxel after platinum chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | docetaxel_label_o12 |
Ramucirumab plus docetaxel after platinum chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | cyramza_label_o12, docetaxel_label_o12 |
Pemetrexed alone after earlier chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | alimta_label_o12 |
Platinum plus pemetrexed after a targeted drug Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | alimta_label_o12 |
Atezolizumab + bevacizumab + paclitaxel + carboplatin Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tecentriq_label_o12, avastin_label_o12 |
Atezolizumab + nab-paclitaxel + carboplatin Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tecentriq_label_o12, abraxane_label_o12 |
Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | opdivo_label_o12, yervoy_label_o12 |
Nivolumab + ipilimumab (PD-L1 at least 1%) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | opdivo_label_o12, yervoy_label_o12 |
Cemiplimab + platinum-based chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | libtayo_label_o12 |
Cemiplimab alone (PD-L1 at least 50%) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | libtayo_label_o12 |
Atezolizumab alone (high PD-L1) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tecentriq_label_o12 |
Durvalumab + tremelimumab + platinum-based chemotherapy Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | imfinzi_label_o12, imjudo_label_o12 |
Pralsetinib Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | gavreto_label_o12 |
Topotecan (into a vein) for platinum-sensitive relapse Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | hycamtin_inj_label_o12 |
Topotecan (capsules) for relapse after a response Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | hycamtin_caps_label_o12 |
Carboplatin + etoposide rechallenge for sensitive relapse (off-label) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy Off-label US pathway; supported by one randomized phase 3 trial (162 patients) | pm_32888454, etoposide_label_o12, carboplatin_label_o12, pdq_sclc |
Lurbinectedin alone for relapse (off-label since 09/2026) Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy Off-label US pathway; the relapsed small-cell indication left the label in 09/2026 | pm_32224306, zepzelca_label_o12, lurbi_b005_ctgov |
Alectinib after another ALK inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | alecensa_label_o12 |
Brigatinib after another ALK inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | alunbrig_label_o12 |
Selpercatinib after another RET inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | retevmo_label_o12 |
Pralsetinib after another RET inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | gavreto_label_o12 |
Capmatinib after another MET inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tabrecta_label_o12 |
Tepotinib after another MET inhibitor Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tepmetko_label_o12 |
Dabrafenib + trametinib after another BRAF/MEK pair Label indication met by the recorded setting; shown unranked beside the other options. | Systemic therapy FDA-approved | tafinlar_label_o12 |